Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blocking Dietary Cholesterol

This article was originally published in Start Up

Executive Summary

One way to block dietary cholesterol is by inhibiting the microsomal triglyceride transfer protein (MTP). MTP is one mechanism used by the liver and by cells in the gut wall (called enterocytes) to process triglycerides and cholesterol for delivery into the systemic circulation. However, past attempts to inhibit MTP (including at Pfizer, BMS, and Bayer) have faltered because of liver toxicity-fatty liver resulting from overaccumulation of LDL. Scientists at Surface Logix think their approach may fare better because it only blocks MTP in the intestine. (Sidebar to "After Statins, What Next?")
Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091563

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel